Cordis
Cordis is a privately held, PE-backed interventional cardiovascular medical device company that designs and sells drug-eluting balloons (SELUTION SLR), vascular closure devices, stents, and endovascular tools to hospitals and physicians across 70+ countries.
- Company typePrivate
- Founded1957
- HeadquartersHialeah, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cordis does
Cordis is a privately held, private-equity-backed interventional cardiovascular medical device company founded in the late 1950s and headquartered in Miami Lakes, Florida, with regional headquarters in Zurich (EMEA) and Singapore (APAC). The company designs, manufactures, and sells drug-eluting balloons (SELUTION SLR), vascular closure devices (MYNX CONTROL, MYNXGRIP, EXOSEAL), self-expanding peripheral and carotid stents (S.M.A.R.T. RADIANZ, PRECISE PRO RX), AAA stent grafts (INCRAFT), vena cava filters (OPTEASE), embolic protection devices (ANGIOGUARD RX), re-entry catheters (OUTBACK Elite), and a broad portfolio of guidewires, diagnostic and guiding catheters, and PTA balloons. Its core technology is the proprietary MicroReservoir sirolimus-release platform combined with Cell Adherent Technology (CAT) on the SELUTION SLR drug-eluting balloon, which delivers sustained limus release for up to 90 days and is positioned as a "metal-free" alternative to drug-eluting stents across coronary and peripheral indications.
The company monetizes primarily through direct sales of hardware devices to hospitals, interventional cardiologists, vascular surgeons, and electrophysiologists across more than 70 countries, with SELUTION SLR commercially available in 65+ countries and investigational in the United States. Pricing is negotiated regionally via direct sales teams, hospital contracts, and group purchasing organizations such as Premier, supplemented by medical education, fellowship grants, and investigator-initiated studies that drive adoption. Cordis is owned by Hellman & Friedman (lead) and KKR (co-investor), who acquired it from Cardinal Health in 2021 for approximately $1 billion, and the company has since deployed significant capital — most notably the up-to-$1.135 billion acquisition of MedAlliance (October 2023) — to position SELUTION SLR as a category-defining asset. Cordis-X, an independent innovation accelerator based in Menlo Park and operated in partnership with Ajax Health, sources next-generation technologies (including the Ladera Large Bore Closure System and the Endovascular Engineering thrombectomy investment) into the Cordis portfolio.
Cordis firmographics
Firmographics- Name
- Cordis
- Legal name
- Cordis US Corp
- Website
- https://cordis.com
- Company type
- Private
- Founded year
- 1957
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Cordis is a privately held, PE-backed interventional cardiovascular medical device company that designs and sells drug-eluting balloons (SELUTION SLR), vascular closure devices, stents, and endovascular tools to hospitals and physicians across 70+ countries.
- Ownership category
- akta.pro rank
Cordis industry classification
Industry- Product category
- Interventional Cardiology & Endovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
- akta.pro secondary industries
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
Keywords
Where Cordis is headquartered
LocationHeadquarters
- HQ city
- Hialeah
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Cordis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Cardiovascular medical device sales: Primary revenue stream from the sale of interventional cardiology and endovascular devices (drug-eluting balloons, vascular closure devices, stent systems, catheters, guidewires) to hospitals and healthcare providers globally across more than 60–70 countries.
- Medical education and grants programs: Cordis supports independent medical education through fellowship grants, educational grants, and investigator-initiated studies, which support adoption of its commercial products but are not directly revenue-generating.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | GPO / negotiated hospital pricing via Premier agreement |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
Cordis product offering
Product offeringCore offering
Cordis manufactures and sells a portfolio of interventional cardiovascular medical devices used by hospitals and physicians for the diagnosis and treatment of coronary and peripheral vascular disease. Its commercial offering spans drug-eluting balloons (SELUTION SLR PTCA and PTA platforms), vascular closure devices (MYNX CONTROL, MYNXGRIP, EXOSEAL), self-expanding and balloon-expandable stents (S.M.A.R.T. RADIANZ, INCRAFT AAA, PALMAZ BLUE, PRECISE), guidewires, diagnostic and guiding catheters, PTA dilatation catheters, embolic protection devices and transradial introducer sheaths. Cordis sells these devices to hospitals and healthcare systems in more than 70 countries through its own direct sales organizations in the Americas, EMEA and APAC.
Product overview
Cordis offers a platform-plus-modules architecture spanning interventional cardiology and peripheral/endovascular interventions, organized across two main portfolios: (1) Interventional Cardiology, anchored by the SELUTION SLR PTCA Drug Eluting Balloon (DEB) using proprietary MicroReservoir sustained sirolimus release, supplemented by MYNX CONTROL / MYNXGRIP / EXOSEAL vascular closure devices, RAIN Sheath transradial introducers, and a full range of guidewires, diagnostic and guiding catheters, and PTCA balloons; and (2) Peripheral Interventions, anchored by the SELUTION SLR PTA Drug Eluting Balloon, the S.M.A.R.T. RADIANZ self-expanding peripheral stent, the BRITE TIP RADIANZ guiding sheath and SABERX RADIANZ PTA dilatation catheter (collectively marketed as the Radianz Radial Peripheral System), the INCRAFT AAA Stent Graft System, the OPTEASE Retrievable Vena Cava Filter, and a full lower-extremity, renal, carotid, and venous portfolio of catheter sheaths, guidewires, diagnostic catheters, and PTA balloons. Cross-cutting products include the ANGIOGUARD RX emboli protection guidewire and the OUTBACK Elite Re-Entry Catheter. Cordis-X serves as an independent innovation accelerator (in partnership with Ajax Health) sourcing new technologies such as the Ladera Large Bore Closure System. Cordis's historical leadership position is rooted in introducing the first guidewire, the first drug-eluting stent (CYPHER), and now the SELUTION SLR DEB platform following the October 2023 MedAlliance acquisition.
Differentiator
Problem solved
Functional benefit
Brands
- Cordis-X: Independent innovation accelerator / growth engine for Cordis, focused on identifying, investing in, and developing next-generation medical device technologies for the Cordis portfolio.
- SELUTION SLR™
- Radianz Radial Peripheral System™
- MYNX CONTROL™
Products and services
- SELUTION SLR PTCA Drug Eluting Balloon (DEB) Latest-generation sirolimus drug-eluting balloon for coronary interventions, using proprietary Cell Adherent Technology (CAT) and MicroReservoirs made from biodegradable polymer mixed with sirolimus to provide controlled and sustained drug release for up to 90 days, designed to deliver drug-eluting stent-equivalent performance without leaving a permanent metal implant.
- SELUTION SLR PTA Drug Eluting Balloon Sirolimus drug-eluting balloon for peripheral (lower extremity / popliteal / SFA) interventions leveraging the MicroReservoir sustained-release technology. Used in the SELUTION SFA Japan Trial and SUCCESS PTA Study demonstrating up to 81.5% 3-year primary patency.
- RAIN Sheath Transradial Hydrophilic Thin-walled Introducer
Companies that use Cordis
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles2 records
Cordis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Cordis partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered strategic public-sector partner, product innovation partnership, background executive affiliation, strategic cybersecurity vendor, u.s. gpo distribution partnership, flagship acquisition / transformational, growth / venous thromboembolism market expansion and flagship / innovation engine partner.
- State of Floridastrategic public-sector partner
- Ladera Medicalproduct innovation partnershipPartnership between Cordis-X and Ladera Medical to develop the Ladera Large Bore Closure System, designed for quick, safe vascular closure after percutaneous catheterization. The FASTEN trial has enrolled its first 25 patients with the goal of obtaining CE Mark approval.
- Cardiovascular Systems, Inc. (CSI)background executive affiliationMatthew Muscari, Cordis President of the Americas, previously led CSI's Peripheral Vascular Commercial organization before joining Cordis; not an active commercial partnership but reflects sector expertise and alumni network.
- Palo Alto Networksstrategic cybersecurity vendorCordis partnered with Palo Alto Networks to deploy a cyber transformation initiative protecting patient data and blocking emerging threats across the enterprise. The collaboration was featured as a customer case study.
- Premier Inc.u.s. gpo distribution partnershipCordis signed a pricing deal with Premier, a major U.S. healthcare group purchasing organization, simultaneously with FDA approval of the MYNX CONTROL Venous Vascular Closure Device. The agreement enables Premier's member hospitals to access Cordis products under negotiated pricing.
- MedAllianceflagship acquisition / transformationalCordis completed the acquisition of Switzerland-based MedAlliance in October 2023 for up to $1.135 billion including milestone payments through 2029 (initial $35M investment, $200M closing payment, up to $125M regulatory milestones, up to $775M commercial milestones). MedAlliance's proprietary SELUTION SLR™ drug-eluting balloon technology is now central to Cordis's coronary and peripheral vascular portfolios, with over 40,000 SELUTION units used in patient treatment to date.
- Endovascular Engineering (E2)growth / venous thromboembolism market expansionCordis made a strategic investment in Endovascular Engineering (E2), a Menlo Park-based developer of next-generation thrombectomy devices for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). The investment expands Cordis's portfolio into the Venous Thromboembolism Market. E2 was founded in 2019 by Dr. Luis Savastano and is also backed by Santé Ventures and another strategic investor.
- Ajax Healthflagship / innovation engine partnerAjax Health partnered with Cordis to lead and fund Cordis-X, Cordis's independent innovation accelerator. Ajax has over 20 years of experience developing medical devices, and Ajax-developed technologies have generated over $750 million in annual revenue for their acquirers and have been used to treat over one million patients. Ajax's CEO Duke Rohlen also serves as CEO of Cordis-X.
Scale indicators12 records
Recent moves9 records
Expansion highlights7 records
Cordis competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Global medical device leader with deep interventional cardiology and peripheral vascular portfolios including drug-eluting stents, balloons, and closure devices. Direct competitor to Cordis in DES, DEB, and vascular closure; serves the same hospitals and interventional cardiologists but at much larger scale.
- Medtronic: Largest medical device company globally, with leading coronary stent (Resolute Onyx), drug-eluting balloon, and peripheral vascular franchises. Competes head-to-head with Cordis across PCI, peripheral, and AAA stent graft markets through its direct sales force and broad hospital contracts.
- Abbott: Major cardiovascular device player with Xience DES, peripheral intervention, and structural heart franchises. Competes with Cordis in coronary stents, imaging, and vascular closure through its large direct sales organization and global hospital footprint.
- Becton Dickinson (BD): BD's Interventional segment (formerly Bard) includes peripheral stents, PTA balloons, drug-coated balloons, and vascular closure devices, directly overlapping Cordis's SFA, BTK, and closure device portfolios. BD's scale and GPO relationships make it one of Cordis's most direct incumbents.
Direct peers
- Terumo: Japanese medical device company with significant interventional cardiology and vascular closure offerings (e.g., TR Band, drug-eluting technologies through Terumo Medical). Competes with Cordis in transradial access sheaths, vascular closure, and coronary intervention products globally.
- Teleflex: Medical device company with vascular closure (e.g., MANTA large-bore closure), interventional cardiology, and peripheral vascular products. Directly competes with Cordis's MYNX CONTROL closure portfolio, particularly in the large-bore structural heart and endovascular space.
Emerging players
- Shockwave Medical: Specialist in intravascular lithotripsy (IVL) for calcium modification in coronary and peripheral interventions. Adjacent disruptor to Cordis's peripheral intervention portfolio; was acquired by Johnson & Johnson, raising competitive intensity in the peripheral space.
- Penumbra: Focused on mechanical thrombectomy and vascular embolization, overlapping with Cordis's E2 investment and broader peripheral/venous portfolio. Competes in the VTE and peripheral arterial thrombectomy segments where Cordis is expanding.
- Inari Medical: Pure-play venous thromboembolism and venous intervention device company (acquired by Stryker). Overlaps with Cordis's E2 thrombectomy investment and the OPTEASE vena cava filter franchise in the venous intervention market.
- AngioDynamics: Mid-cap medical device company focused on peripheral vascular disease and venous intervention, with overlapping product lines in PTA balloons, thrombectomy, and venous access. Smaller scale than Cordis but competes in similar hospital accounts for peripheral intervention procedures.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Cordis social profiles
Digital presenceCordis compliance and trust
Trust signalCompliance4 records
Cordis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cordis leadership team
Management profileNumber of profiles
Profiles10 records
Cordis subsidiaries and ownership
Company hierarchySubsidiaries3 records
Cordis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cordis M&A and investment
M&A and investmentM&A4 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cordis
What does Cordis do?
Cordis manufactures and sells a portfolio of interventional cardiovascular medical devices used by hospitals and physicians for the diagnosis and treatment of coronary and peripheral vascular disease. Its commercial offering spans drug-eluting balloons (SELUTION SLR PTCA and PTA platforms), vascular closure devices (MYNX CONTROL, MYNXGRIP, EXOSEAL), self-expanding and balloon-expandable stents (S.M.A.R.T. RADIANZ, INCRAFT AAA, PALMAZ BLUE, PRECISE), guidewires, diagnostic and guiding catheters, PTA dilatation catheters, embolic protection devices and transradial introducer sheaths. Cordis sells these devices to hospitals and healthcare systems in more than 70 countries through its own direct sales organizations in the Americas, EMEA and APAC.
Is Cordis a public or private company?
Cordis is a private company. It is classified as private equity controlled and is currently operating.
When was Cordis founded?
Cordis was founded in 1957. It employs 1,001 to 5,000 people.
Where is Cordis based?
Cordis is headquartered in Hialeah, United States, in the North America region.
How does Cordis make money?
Two revenue lines are on record. Cardiovascular medical device sales are the primary driver. The others are medical education and grants programs.
Who are Cordis's main competitors?
Broad incumbents on record are Boston Scientific, Medtronic, Abbott and Becton Dickinson (BD). Direct peers are Terumo and Teleflex. Emerging players are Shockwave Medical, Penumbra, Inari Medical and AngioDynamics.
Does Cordis have an API?
No public API is recorded for Cordis.
What industry is Cordis in?
Cordis's product category is Interventional Cardiology & Endovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.